Bimekizumab

Last Updated: 06/30/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 486 publications

Bimekizumab Long-Term Safety and Efficacy Across the Spectrum of Axial Spondyloarthritis Over 3 Years: Results from Two Phase 3 Studies.

Bimekizumab Long-Term Safety and Efficacy Across the Spectrum of Axial Spondyloarthritis Over 3 Years: Results from Two Phase 3 Studies.

Journal: The Journal of rheumatology

Published: June 15, 2026

Refractory acute generalized exanthematous pustulosis-Successfully treated with bimekizumab.

Refractory acute generalized exanthematous pustulosis-Successfully treated with bimekizumab.

Journal: JAAD case reports

Published: June 08, 2026

Severe Nail Psoriasis and Early Psoriatic Arthritis: Illustrative Cases Confirming That Severity of Disease Is Not Solely Dependent on the Extent of Body Surface Area.

Severe Nail Psoriasis and Early Psoriatic Arthritis: Illustrative Cases Confirming That Severity of Disease Is Not Solely Dependent on the Extent of Body Surface Area.

Journal: The Journal of clinical and aesthetic dermatology

Published: June 04, 2026

IL-17 inhibitor therapy and risk of chronic obstructive pulmonary disease and related pulmonary outcomes in patients with psoriasis: A real-world cohort study.

IL-17 inhibitor therapy and risk of chronic obstructive pulmonary disease and related pulmonary outcomes in patients with psoriasis: A real-world cohort study.

Journal: Respiratory medicine

Published: May 07, 2026

Bimekizumab for refractory hidradenitis suppurativa and associated inflammatory arthropathies.

Bimekizumab for refractory hidradenitis suppurativa and associated inflammatory arthropathies.

Journal: JAAD case reports

Published: May 06, 2026

Drug survival of bimekizumab, guselkumab, and risankizumab after secondary IL-17 inhibitor failure.

Drug survival of bimekizumab, guselkumab, and risankizumab after secondary IL-17 inhibitor failure.

Journal: Journal of the European Academy of Dermatology and Venereology : JEADV

Published: May 05, 2026

Targeted Prevention and Management of Mucocutaneous Candidiasis During Bimekizumab Therapy in Hidradenitis Suppurativa: A Practical Clinical Perspective.

Targeted Prevention and Management of Mucocutaneous Candidiasis During Bimekizumab Therapy in Hidradenitis Suppurativa: A Practical Clinical Perspective.

Journal: International journal of dermatology

Published: April 25, 2026

Diagnostic and therapeutic challenges in concomitant axial spondyloarthritis and rheumatoid arthritis: a case-based review.

Diagnostic and therapeutic challenges in concomitant axial spondyloarthritis and rheumatoid arthritis: a case-based review.

Journal: Rheumatology international

Published: April 22, 2026

Comparative Effectiveness of Four Biologics for Moderate-to-Severe Plaque Psoriasis: A Network Meta-Analysis.

Comparative Effectiveness of Four Biologics for Moderate-to-Severe Plaque Psoriasis: A Network Meta-Analysis.

Journal: Cureus

Published: April 21, 2026

Efficacy of Bimekizumab on Palmoplantar Psoriasis: A 16-Week Multicenter Retrospective Study-IL PSO (Italian Landscape PSOriasis).

Efficacy of Bimekizumab on Palmoplantar Psoriasis: A 16-Week Multicenter Retrospective Study-IL PSO (Italian Landscape PSOriasis).

Journal: Journal of clinical medicine

Published: April 17, 2026

Postmarketing safety of bimekizumab for hidradenitis suppurativa: An early pharmacovigilance analysis using the United States Food and Drug Administration Adverse Event Reporting System.

Postmarketing safety of bimekizumab for hidradenitis suppurativa: An early pharmacovigilance analysis using the United States Food and Drug Administration Adverse Event Reporting System.

Journal: JAAD international

Published: April 13, 2026

Correction: Comparative Effectiveness of Bimekizumab and Secukinumab in Patients with Psoriatic Arthritis at 52 Weeks Using a Matching-Adjusted Indirect Comparison.

Correction: Comparative Effectiveness of Bimekizumab and Secukinumab in Patients with Psoriatic Arthritis at 52 Weeks Using a Matching-Adjusted Indirect Comparison.

Journal: Rheumatology and therapy

Published: April 08, 2026

Showing 1-12 of 486

Last Updated: 06/30/2026